Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT07535606
Active, not recruiting Phase 1

A Study to Evaluate ALN-4915 in Adult Healthy Volunteers

NCT07535606 · tracked via the Priya Life Science UK tracker
Sponsor
Alnylam Pharmaceuticals
Phase
Phase 1
Started
2026-03-02
Last updated
2026-10-15

Condition(s) studied

Healthy Volunteers

Investigational drug(s) / intervention(s)

ALN-4915Placebo

ALN-4915: ALN-4915 will be administered subcutaneously (SC)

Placebo: Placebo will be administered SC

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Is willing and able to complete all study assessments Exclusion Criteria: * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN) * Has total bilirubin \>ULN * Has no history of invasive infection by an encapsulated organism * Has no known complement or immunologic deficiency

Primary outcome measure(s)

  • Frequency of Adverse Events — Serious adverse events (SAEs) after signing of ICF up to Month 12; nonserious AEs after first dose of study drug up to Month 12

Trial sites (1)

FacilityCityRegionStatus
Clinical Trial Site London United Kingdom

More Alnylam Pharmaceuticals trials in the UK

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Recruiting
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers Recruiting
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB Recruiting
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease Recruiting
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) Recruiting

Other trials for the same condition

Nasal Residency of HEX17 Starting soon
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers Recruiting
ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression Active, not recruiting
Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older Recruiting
Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07535606 on ClinicalTrials.gov ↗ ← All trials in the UK